Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: In the 2019 WHO FOR NEN’S classification NETG3 have been distinguished from poorly differentiated neuroendocrine carcinoma (NEC). They are heterogeneous group concerning prognosis and treatment benefit.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Ruiz G, Graselli J, Golubicki M, Rizzol M,
Keywords: G3 NEN, PD-L1, KRAS, BIOMARKERS,
#2938 Rectal Neuroendocrine Tumor with Concomitant Erdheim-Chester Disease: A Rare Case Report
Introduction: Rectal neuroendocrine tumor (NET), a type of rare tumor, is rather rarer when accompanied by non-Langerhans cells histiocytosis named Erdheim-Chester disease (ECD).
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Zhang Y, Liu M, Chen L, Guo Y, Chen M,
Keywords: rectal neuroendocrine tumor, Erdheim-Chester disease.,
Introduction: Molecular genomic analyses are widely used in oncology but experience in advanced neuroendocrine neoplasms (NENs) is still limited.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Garcia Alvarez A
Authors: Garcia-Alvarez A, Hernando J, Vivancos A, Landolfi S, Casteras A,
Introduction: Gastro-entero-pancreatic neuroendocrine tumors (GEP-NET) are a heterogeneous tumor entity with respect to biological behaviour and prognosis. This makes diagnosis and treatment a major challenge.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Siebenhüner A
Authors: Duschek S, Weber A, Curioni-Fontecedro A, Siebenhüner A,
Keywords: Biomarker, immunohistochemistry, GEP-NET, TMA, Prognosis, hormone receptor,
Introduction: Target therapy has improved the outcome of neuroendocrine tumors (NETs), but little is known about the strategies to overcome the acquired resistance. MET is considered one of the putative mechanisms of resistance. RET is also rearranged in some other endocrine tumors (like thyroid).
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Cella C, Barberis M, Spad F, Pisa E, Laffi A,
Keywords: Everolimus, MET, RET,